Last 12 months
Inside the activity.
0 purchase rows · 19 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 3 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 8 |
| Sep 2026 | 0 | 5 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2021 Filed Mar 10, 2021 02:08 UTC |
McGrody Kevin JChief Accounting Officer
|
Exercise / conversionCommon Stock · Derivative | 671 | $0.00 | $0.00 |
DisclosureSEC source: 0001615192-21-000001 · edgardoc.xml · derivative · entry 8 McGrody Kevin J · CIK 0001615192 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 671 shares Expires 2021-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These securities are Restricted Stock Units. F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the Restricted Stock Units. F3 · derivative.exercise_date: One third of the units subject to the award shall vest on each of the first, second, and third anniversaries of the grant date. Read SEC document |
| March 06, 2021 Filed Mar 10, 2021 02:08 UTC |
McGrody Kevin JChief Accounting Officer
|
Tax withholdingCommon Stock | 466 | $0.00 | $0.00 |
DisclosureSEC source: 0001615192-21-000001 · edgardoc.xml · nonDerivative · entry 6 McGrody Kevin J · CIK 0001615192 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,548 Read SEC document |
| March 06, 2021 Filed Mar 10, 2021 02:08 UTC |
McGrody Kevin JChief Accounting Officer
|
Exercise / conversionCommon Stock | 886 | $0.00 | $0.00 |
DisclosureSEC source: 0001615192-21-000001 · edgardoc.xml · nonDerivative · entry 5 McGrody Kevin J · CIK 0001615192 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These securities are Restricted Stock Units. Read SEC document |
| March 06, 2021 Filed Mar 10, 2021 02:08 UTC |
McGrody Kevin JChief Accounting Officer
|
Tax withholdingCommon Stock | 532 | $0.00 | $0.00 |
DisclosureSEC source: 0001615192-21-000001 · edgardoc.xml · nonDerivative · entry 4 McGrody Kevin J · CIK 0001615192 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,128 Read SEC document |
| March 06, 2021 Filed Mar 10, 2021 02:08 UTC |
McGrody Kevin JChief Accounting Officer
|
Exercise / conversionCommon Stock | 1,011 | $0.00 | $0.00 |
DisclosureSEC source: 0001615192-21-000001 · edgardoc.xml · nonDerivative · entry 3 McGrody Kevin J · CIK 0001615192 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These securities are Restricted Stock Units. Read SEC document |
| March 06, 2021 Filed Mar 10, 2021 02:08 UTC |
McGrody Kevin JChief Accounting Officer
|
Tax withholdingCommon Stock | 353 | $0.00 | $0.00 |
DisclosureSEC source: 0001615192-21-000001 · edgardoc.xml · nonDerivative · entry 2 McGrody Kevin J · CIK 0001615192 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,649 Read SEC document |
| March 06, 2021 Filed Mar 10, 2021 02:08 UTC |
McGrody Kevin JChief Accounting Officer
|
Exercise / conversionCommon Stock | 671 | $0.00 | $0.00 |
DisclosureSEC source: 0001615192-21-000001 · edgardoc.xml · nonDerivative · entry 1 McGrody Kevin J · CIK 0001615192 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,002 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These securities are Restricted Stock Units. Read SEC document |
| March 06, 2021 Filed Mar 10, 2021 01:47 UTC |
Sanzone Virginia RuthVP, General Counsel
|
Exercise / conversionPerformance Shares · Derivative | 1,595 | $0.00 | $0.00 |
DisclosureSEC source: 0001669639-21-000003 · edgardoc.xml · derivative · entry 6 Sanzone Virginia Ruth · CIK 0001669639 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,190 Underlying: Common Stock · 1,595 shares Expires 2023-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These Securities are Performance-based Restricted Stock Units (PRSU). F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the PRSUs. F4 · derivative.exercise_date: These PRSUs were granted on March 6, 2020. Vesting of these performance stock units are subject to the satisfaction of both performance-based conditions and time-based criteria. These PRSUs vest on March 6 of the first, second, and third year following the year of grant. Read SEC document |
| March 06, 2021 Filed Mar 10, 2021 01:47 UTC |
Sanzone Virginia RuthVP, General Counsel
|
Exercise / conversionPerformance Shares · Derivative | 1,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001669639-21-000003 · edgardoc.xml · derivative · entry 5 Sanzone Virginia Ruth · CIK 0001669639 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,444 Underlying: Common Stock · 1,444 shares Expires 2022-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These Securities are Performance-based Restricted Stock Units (PRSU). F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the PRSUs. F3 · derivative.exercise_date: These PRSUs were granted on March 6, 2019. Vesting of these performance stock units are subject to the satisfaction of both performance-based conditions and time-based criteria. These PRSUs vest on March 6 of the first, second, and third year following the year of grant. Read SEC document |
| March 06, 2021 Filed Mar 10, 2021 01:47 UTC |
Sanzone Virginia RuthVP, General Counsel
|
Tax withholdingCommon Stock | 839 | $0.00 | $0.00 |
DisclosureSEC source: 0001669639-21-000003 · edgardoc.xml · nonDerivative · entry 4 Sanzone Virginia Ruth · CIK 0001669639 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,388 Read SEC document |
| March 06, 2021 Filed Mar 10, 2021 01:47 UTC |
Sanzone Virginia RuthVP, General Counsel
|
Exercise / conversionCommon Stock | 1,595 | $0.00 | $0.00 |
DisclosureSEC source: 0001669639-21-000003 · edgardoc.xml · nonDerivative · entry 3 Sanzone Virginia Ruth · CIK 0001669639 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,227 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These Securities are Performance-based Restricted Stock Units (PRSU). Read SEC document |
| March 06, 2021 Filed Mar 10, 2021 01:47 UTC |
Sanzone Virginia RuthVP, General Counsel
|
Tax withholdingCommon Stock | 760 | $0.00 | $0.00 |
DisclosureSEC source: 0001669639-21-000003 · edgardoc.xml · nonDerivative · entry 2 Sanzone Virginia Ruth · CIK 0001669639 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,632 Read SEC document |
| March 06, 2021 Filed Mar 10, 2021 01:47 UTC |
Sanzone Virginia RuthVP, General Counsel
|
Exercise / conversionCommon Stock | 1,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001669639-21-000003 · edgardoc.xml · nonDerivative · entry 1 Sanzone Virginia Ruth · CIK 0001669639 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These Securities are Performance-based Restricted Stock Units (PRSU). Read SEC document |
| March 02, 2021 Filed Mar 2, 2021 22:07 UTC |
SWINNEY ROBERT SDirector
|
SaleCommon Stock | 1,500 | $207.00 | $310,500.00 |
DisclosureSEC source: 0001073398-21-000002 · edgardoc.xml · nonDerivative · entry 1 SWINNEY ROBERT S · CIK 0001073398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,505 F1 · price: All shares sold were sold at the exact price disclosed. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 22:36 UTC |
Voigtlander Christian B.Chief Operating Officer
|
Exercise / conversionPerformance Shares · Derivative | 3,519 | $0.00 | $0.00 |
DisclosureSEC source: 0001727477-21-000001 · edgardoc.xml · derivative · entry 3 Voigtlander Christian B. · CIK 0001727477 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,519 shares Expires 2021-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These Securities are Performance-based Restricted Stock Units (PRSU). F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the PRSUs. F3 · derivative.exercise_date: These PRSUs were granted on March 6, 2018. Vesting of these performance stock units are subject to the satisfaction of both performance-based conditions and time-based criteria. These PRSUs had a February 15 vest date subject to approval by the Compensation Committee, which occurred on February 18. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 22:36 UTC |
Voigtlander Christian B.Chief Operating Officer
|
Tax withholdingCommon Stock | 1,873 | $0.00 | $0.00 |
DisclosureSEC source: 0001727477-21-000001 · edgardoc.xml · nonDerivative · entry 2 Voigtlander Christian B. · CIK 0001727477 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,076 Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 22:36 UTC |
Voigtlander Christian B.Chief Operating Officer
|
Exercise / conversionCommon Stock | 3,519 | $0.00 | $0.00 |
DisclosureSEC source: 0001727477-21-000001 · edgardoc.xml · nonDerivative · entry 1 Voigtlander Christian B. · CIK 0001727477 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These Securities are Performance-based Restricted Stock Units (PRSU). Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 22:31 UTC |
Jain VivekDirector · Chairman and CEO
|
Exercise / conversionPerformance Shares · Derivative | 8,044 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001410442-21-000005 · edgardoc.xml · derivative · entry 4 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,044 shares Expires 2021-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These Securities are Performance-based Restricted Stock Units (PRSU). F3 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the PRSUs. F4 · derivative.exercise_date: These PRSUs were granted on March 6, 2018. Vesting of these performance stock units are subject to the satisfaction of both performance-based conditions and time-based criteria. These PRSUs had a February 15 vest date subject to approval by the Compensation Committee, which occurred on February 18. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 22:31 UTC |
Jain VivekDirector · Chairman and CEO
|
Tax withholdingCommon Stock | 4,235 | $0.00 | $0.00 |
DisclosureSEC source: 0001410442-21-000005 · edgardoc.xml · nonDerivative · entry 2 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,050 Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 22:31 UTC |
Jain VivekDirector · Chairman and CEO
|
Exercise / conversionCommon Stock | 8,044 | $0.00 | $0.00 |
DisclosureSEC source: 0001410442-21-000005 · edgardoc.xml · nonDerivative · entry 1 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,285 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These Securities are Performance-based Restricted Stock Units (PRSU). Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 22:27 UTC |
Woolson DanielVP, GM-Infusion Capital
|
Exercise / conversionPerformance Shares · Derivative | 804 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001698998-21-000002 · edgardoc.xml · derivative · entry 3 Woolson Daniel · CIK 0001698998 · VP, GM-Infusion Capital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 804 shares Expires 2021-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These Securities are Performance-based Restricted Stock Units (PRSU). F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the PRSUs. F3 · derivative.exercise_date: These PRSUs were granted on March 6, 2018. Vesting of these performance stock units are subject to the satisfaction of both performance-based conditions and time-based criteria. These PRSUs had a February 15 vest date subject to approval by the Compensation Committee, which occurred on February 18. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 22:27 UTC |
Woolson DanielVP, GM-Infusion Capital
|
Tax withholdingCommon Stock | 377 | $0.00 | $0.00 |
DisclosureSEC source: 0001698998-21-000002 · edgardoc.xml · nonDerivative · entry 2 Woolson Daniel · CIK 0001698998 · VP, GM-Infusion Capital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,567 Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 22:27 UTC |
Woolson DanielVP, GM-Infusion Capital
|
Exercise / conversionCommon Stock | 804 | $0.00 | $0.00 |
DisclosureSEC source: 0001698998-21-000002 · edgardoc.xml · nonDerivative · entry 1 Woolson Daniel · CIK 0001698998 · VP, GM-Infusion Capital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These Securities are Performance-based Restricted Stock Units (PRSU). Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 22:15 UTC |
Sanzone Virginia RuthVP, General Counsel
|
Exercise / conversionPerformance Shares · Derivative | 1,005 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001669639-21-000002 · edgardoc.xml · derivative · entry 3 Sanzone Virginia Ruth · CIK 0001669639 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,005 shares Expires 2021-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These Securities are Performance-based Restricted Stock Units (PRSU). F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the PRSUs. F3 · derivative.exercise_date: These PRSUs were granted on March 6, 2018. Vesting of these performance stock units are subject to the satisfaction of both performance-based conditions and time-based criteria. These PRSUs had a February 15 vest date subject to approval by the Compensation Committee, which occurred on February 18. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 22:15 UTC |
Sanzone Virginia RuthVP, General Counsel
|
Tax withholdingCommon Stock | 554 | $0.00 | $0.00 |
DisclosureSEC source: 0001669639-21-000002 · edgardoc.xml · nonDerivative · entry 2 Sanzone Virginia Ruth · CIK 0001669639 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,948 Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 22:15 UTC |
Sanzone Virginia RuthVP, General Counsel
|
Exercise / conversionCommon Stock | 1,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001669639-21-000002 · edgardoc.xml · nonDerivative · entry 1 Sanzone Virginia Ruth · CIK 0001669639 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These Securities are Performance-based Restricted Stock Units (PRSU). Read SEC document |
| February 02, 2021 Filed Feb 2, 2021 22:01 UTC |
SWINNEY ROBERT SDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $43.12 | $0.00 |
DisclosureSEC source: 0001073398-21-000001 · edgardoc.xml · derivative · entry 3 SWINNEY ROBERT S · CIK 0001073398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2021-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2021 Filed Feb 2, 2021 22:01 UTC |
SWINNEY ROBERT SDirector
|
Exercise / conversionCommon Stock | 1,500 | $43.12 | $64,680.00 |
DisclosureSEC source: 0001073398-21-000001 · edgardoc.xml · nonDerivative · entry 1 SWINNEY ROBERT S · CIK 0001073398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2021 Filed Jan 8, 2021 22:11 UTC |
Jain VivekDirector · Chairman and CEO
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 38,591 | $0.00 Strike: $58.79 | $0.00 |
DisclosureSEC source: 0001410442-21-000002 · edgardoc.xml · derivative · entry 11 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,366 Underlying: Common Stock · 38,591 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. F5 · derivative.exercise_date: Options vest and are exercisable as to 25% of the underlying grant one year after the vesting commencement date of February 13, 2014 and in equal monthly installments thereafter for three additional years. Read SEC document |
| January 08, 2021 Filed Jan 8, 2021 22:11 UTC |
Jain VivekDirector · Chairman and CEO
|
SaleCommon Stock | 38,591 | $220.00 | $8,490,020.00 |
DisclosureSEC source: 0001410442-21-000002 · edgardoc.xml · nonDerivative · entry 7 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,241 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. Read SEC document |
| January 08, 2021 Filed Jan 8, 2021 22:11 UTC |
Jain VivekDirector · Chairman and CEO
|
Exercise / conversionCommon Stock | 38,591 | $58.79 | $2,268,764.89 |
DisclosureSEC source: 0001410442-21-000002 · edgardoc.xml · nonDerivative · entry 6 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,832 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 22:11 UTC |
Jain VivekDirector · Chairman and CEO
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,070 | $0.00 Strike: $58.79 | $0.00 |
DisclosureSEC source: 0001410442-21-000002 · edgardoc.xml · derivative · entry 10 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,957 Underlying: Common Stock · 6,070 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. F5 · derivative.exercise_date: Options vest and are exercisable as to 25% of the underlying grant one year after the vesting commencement date of February 13, 2014 and in equal monthly installments thereafter for three additional years. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 22:11 UTC |
Jain VivekDirector · Chairman and CEO
|
SaleCommon Stock | 6,070 | $220.00 | $1,335,400.00 |
DisclosureSEC source: 0001410442-21-000002 · edgardoc.xml · nonDerivative · entry 5 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,241 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. F3 · price: All shares sold were sold at the exact price disclosed. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 22:11 UTC |
Jain VivekDirector · Chairman and CEO
|
Exercise / conversionCommon Stock | 6,070 | $58.79 | $356,855.30 |
DisclosureSEC source: 0001410442-21-000002 · edgardoc.xml · nonDerivative · entry 4 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,311 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:11 UTC |
Jain VivekDirector · Chairman and CEO
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,973 | $0.00 Strike: $58.79 | $0.00 |
DisclosureSEC source: 0001410442-21-000002 · edgardoc.xml · derivative · entry 9 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389,027 Underlying: Common Stock · 10,973 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. F5 · derivative.exercise_date: Options vest and are exercisable as to 25% of the underlying grant one year after the vesting commencement date of February 13, 2014 and in equal monthly installments thereafter for three additional years. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:11 UTC |
Jain VivekDirector · Chairman and CEO
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 13,366 | $0.00 Strike: $58.79 | $0.00 |
DisclosureSEC source: 0001410442-21-000002 · edgardoc.xml · derivative · entry 8 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 13,366 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. F4 · derivative.exercise_date: Twenty-five percent of the shares shall vest on each of the first, second,third, and fourth anniversaries of the vesting commencement date of February 13, 2014. Fifty percent of the vested shares shall become exercisable if, during the term of the option, the closing price of the Company's common stock is equal to or more than one-hundred and twenty-five percent of the exercise price per share for thirty consecutive trading days. The remaining fifty percent of the vested shares shall become exercisable if, after the date of award and on or before the expiration date, the closing price of the Company's common stock is equal to or more than one-hundred and fifty percent of the exercise price for 30 consecutive trading days. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:11 UTC |
Jain VivekDirector · Chairman and CEO
|
SaleCommon Stock | 24,339 | $220.00 | $5,354,580.00 |
DisclosureSEC source: 0001410442-21-000002 · edgardoc.xml · nonDerivative · entry 3 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,241 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. F3 · price: All shares sold were sold at the exact price disclosed. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:11 UTC |
Jain VivekDirector · Chairman and CEO
|
Exercise / conversionCommon Stock | 10,973 | $58.79 | $645,102.67 |
DisclosureSEC source: 0001410442-21-000002 · edgardoc.xml · nonDerivative · entry 2 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:11 UTC |
Jain VivekDirector · Chairman and CEO
|
Exercise / conversionCommon Stock | 13,366 | $58.79 | $785,787.14 |
DisclosureSEC source: 0001410442-21-000002 · edgardoc.xml · nonDerivative · entry 1 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,607 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:15 UTC |
Jain VivekDirector · Chairman and CEO
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 11,500 | $0.00 Strike: $58.79 | $0.00 |
DisclosureSEC source: 0001410442-21-000001 · edgardoc.xml · derivative · entry 10 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,366 Underlying: Common Stock · 11,500 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. F10 · derivative.exercise_date: Twenty-five percent of the shares shall vest on each of the first, second,third, and fourth anniversaries of the vesting commencement date of February 13, 2014. Fifty percent of the vested shares shall become exercisable if, during the term of the option, the closing price of the Company's common stock is equal to or more than one-hundred and twenty-five percent of the exercise price per share for thirty consecutive trading days. The remaining fifty percent of the vested shares shall become exercisable if, after the date of award and on or before the expiration date, the closing price of the Company's common stock is equal to or more than one-hundred and fifty percent of the exercise price for 30 consecutive trading days. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:15 UTC |
Jain VivekDirector · Chairman and CEO
|
SaleCommon Stock | 200 | $216.42 | $43,283.96 |
DisclosureSEC source: 0001410442-21-000001 · edgardoc.xml · nonDerivative · entry 9 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,241 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.29 to $216.72, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:15 UTC |
Jain VivekDirector · Chairman and CEO
|
SaleCommon Stock | 1,533 | $215.58 | $330,477.24 |
DisclosureSEC source: 0001410442-21-000001 · edgardoc.xml · nonDerivative · entry 8 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,441 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.11 to $214.77, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:15 UTC |
Jain VivekDirector · Chairman and CEO
|
SaleCommon Stock | 300 | $214.33 | $64,299.99 |
DisclosureSEC source: 0001410442-21-000001 · edgardoc.xml · nonDerivative · entry 7 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,974 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.11 to $214.77, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:15 UTC |
Jain VivekDirector · Chairman and CEO
|
SaleCommon Stock | 708 | $213.45 | $151,124.65 |
DisclosureSEC source: 0001410442-21-000001 · edgardoc.xml · nonDerivative · entry 6 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,274 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.91 to $213.78, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:15 UTC |
Jain VivekDirector · Chairman and CEO
|
SaleCommon Stock | 4,759 | $212.10 | $1,009,376.76 |
DisclosureSEC source: 0001410442-21-000001 · edgardoc.xml · nonDerivative · entry 5 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,982 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.89 to $212.87, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:15 UTC |
Jain VivekDirector · Chairman and CEO
|
SaleCommon Stock | 2,500 | $211.54 | $528,847.00 |
DisclosureSEC source: 0001410442-21-000001 · edgardoc.xml · nonDerivative · entry 4 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,741 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.86 to $211.72, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:15 UTC |
Jain VivekDirector · Chairman and CEO
|
SaleCommon Stock | 700 | $210.30 | $147,211.47 |
DisclosureSEC source: 0001410442-21-000001 · edgardoc.xml · nonDerivative · entry 3 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,241 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.84 to $210.55, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:15 UTC |
Jain VivekDirector · Chairman and CEO
|
SaleCommon Stock | 800 | $209.24 | $167,390.56 |
DisclosureSEC source: 0001410442-21-000001 · edgardoc.xml · nonDerivative · entry 2 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,941 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $208.65 to $209.61, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:15 UTC |
Jain VivekDirector · Chairman and CEO
|
Exercise / conversionCommon Stock | 11,500 | $58.79 | $676,085.00 |
DisclosureSEC source: 0001410442-21-000001 · edgardoc.xml · nonDerivative · entry 1 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. Read SEC document |
| December 04, 2020 Filed Dec 7, 2020 23:06 UTC |
Jain VivekDirector · Chairman and CEO
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 9,200 | $0.00 Strike: $58.79 | $0.00 |
DisclosureSEC source: 0001410442-20-000011 · edgardoc.xml · derivative · entry 6 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,866 Underlying: Common Stock · 9,200 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2020. F4 · derivative.exercise_date: Twenty-five percent of the shares shall vest on each of the first, second,third, and fourth anniversaries of the vesting commencement date of February 13, 2014. Fifty percent of the vested shares shall become exercisable if, during the term of the option, the closing price of the Company's common stock is equal to or more than one-hundred and twenty-five percent of the exercise price per share for thirty consecutive trading days. The remaining fifty percent of the vested shares shall become exercisable if, after the date of award and on or before the expiration date, the closing price of the Company's common stock is equal to or more than one-hundred and fifty percent of the exercise price for 30 consecutive trading days. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.